| Literature DB >> 31910150 |
Abstract
Insufficient insulin release plays a crucial role in the development of unhealthy status in patients with obesity; the present study aimed to classify these patients by the indices for insulin resistance and insulin release. After the indices from OGTT were assessed to achieve high differentiability and low redundancy in classifying patients, HOMA-IR and IGI30min were chosen to classify the patients using K-means clustering method. A total of 249 non-diabetic patients with obesity were classified into four groups. In Group 1, 19 patients were characteristic of high insulin resistance and high insulin release, as well as well-controlled glucose levels, the highest BMI, the youngest age, and the highest early phase release of insulin. In Group 2, 38 patients were unhealthiest in terms of high insulin resistance, reduced insulin release and IGT status. Group 3 consisted of 63 patients that were healthiest with low insulin resistance and high insulin release. In Group 4, 46 IGT patients and 14 IFG patients were identified among 129 patients that showed low insulin resistance, low insulin release, moderate obesity and older age. These concurrent impotent insulin release, older age, and moderate obesity indicated decreasing obesity with increasing age and reduced insulin release. The classification of patients with obesity using K-means clustering method by HOMA-IR and IGI30min provides more information about the development of obesity and unhealthy status. The patients with distinct insulin resistance and insulin release should be followed up, especially for those with reduced or even absent insulin response to glucose stimulation.Entities:
Keywords: K-means clustering; insulin resistance; oral glucose tolerance test; pancreatic β-cell function; patients with obesity
Year: 2020 PMID: 31910150 PMCID: PMC6993255 DOI: 10.1530/EC-19-0476
Source DB: PubMed Journal: Endocr Connect ISSN: 2049-3614 Impact factor: 3.335
Calculated indices from OGTT results.
| Usage | Index name | Equation | Units (glucose; insulin) | Reference |
|---|---|---|---|---|
| Insulin resistance | HOMA-IR | FPG × fasting insulin/22.5 | mmol/L; mIU/L | (9) |
| ISI | mg/dL; mIU/L | (10) | ||
| Insulin release (β-cell function) | HOMA-β | 20 × fasting insulin/(FBG − 3.5) | mmol/L; mIU/L | (9) |
| IGI30min | (Insulin30min − insulin0min)/(glucose30min − glucose0min) | mmol/L; mIU/L | (11) | |
| 1st PH | 1283 + 1.829 × Insulin30m − 138.7 × Glucose30m + 3.772 × Insulin0m | mmol/L; pmol/L | (12) | |
| 2nd PH | 393 + 1.163 × Insulin0m − 40.72 × Glucose120m + 0.313 × Insulin120m | mmol/L; pmol/L | (12) | |
| Disposition index (DI) | IGI30/fasting insulin | mmol/L; mIU/L | (13) | |
Characteristics of NGT, IGT, IFG, and T2DM patients regarding obesity levels, glucose metabolism, insulin resistance and β-cell function.
| Categories | Variables | Mean ± | ||||
|---|---|---|---|---|---|---|
| NGT | IGT | IFG | T2DM | Total | ||
| Number of patients | 138 | 62 | 37 | 12 | 249 | |
| Physical examination | Age | 27.9 ± 8.2 | 33.9 ± 10.6 | 31.2 ± 7.2 | 40.6 ± 13.9 | 30.5 ± 9.6 |
| Weight | 91.6 ± 16.5 | 92.6 ± 20.0 | 101.0 ± 22.0 | 95.1 ± 18.8 | 93.3 ± 18.5 | |
| BMI | 32.8 ± 4.4 | 33.5 ± 4.8 | 35.6 ± 5.9 | 36.2 ± 6.5 | 33.5 ± 4.9 | |
| WHR | 0.92 ± 0.07 | 0.95 ± 0.07 | 0.95 ± 0.07 | 0.95 ± 0.04 | 0.93 ± 0.07 | |
| SBP | 129 ± 12 | 135 ± 15 | 132 ± 14 | 137 ± 12 | 131 ± 134 | |
| Laboratory measurement | HbA1C | 5.3 ± 0.38 | 5.8 ± 0.5 | 5.6 ± 0.4 | 6.0 ± 0.5 | 5.5 ± 0.5 |
| FBG | 5.1 ± 0.3 | 5.6 ± 0.7 | 5.9 ± 0.3 | 6.1 ± 0.7 | 5.4 ± 0.6 | |
| PBG30min | 8.5 ± 1.2 | 9.6 ± 1.5 | 9.4 ± 1.8 | 10.9 ± 2.0 | 9.1 ± 1.6 | |
| PBG2h | 6.0 ± 1.0 | 8.9 ± 0.8 | 6.3 ± 1.0 | 12.2 ± 1.3 | 7.1 ± 2.0 | |
| FINS | 25 ± 13 | 30 ± 22 | 32 ± 20 | 31 ± 16 | 27 ± 17 | |
| INS30min | 185 ± 140 | 134 ± 99 | 159 ± 101 | 112 ± 93 | 164 ± 125 | |
| INS2h | 97 ± 104 | 170 ± 108 | 97 ± 76 | 188 ± 95 | 120 ± 106 | |
| Insulin resistance | HOMA-IR | 5.5 ± 3.0 | 7.6 ± 5.7 | 8.6 ± 5.3 | 8.6 ± 5.1 | 6.7 ± 4.4 |
| ISI | 3.7 ± 1.8 | 2.2 ± 1.1 | 2.7 ± 1.5 | 1.7 ± 0.9 | 3.0 ± 1.7 | |
| Insulin release (β-cell function) | HOMA-β | 327 ± 226 | 303 ± 220 | 273 ± 176 | 236 ± 93 | 307 ± 213 |
| IGI30min | 48.6 ± 45.8 | 24.6 ± 32.4 | 39.4 ± 25.6 | 15.3 ± 10.6 | 39.3 ± 40.4 | |
| 1st PH | 3105 ± 1974 | 2442 ± 1725 | 2852 ± 1647 | 1999 ± 1331 | 2832 ± 1855 | |
| 2nd PH | 560 ± 290 | 641 ± 390 | 609 ± 263 | 550 ± 313 | 587 ± 314 | |
| Disposition index (DI) | 2.2 ± 1.9 | 0.9 ± 1.4 | 1.4 ± 1.0 | 0.5 ± 0.3 | 1.7 ± 1.7 | |
Glucose is expressed in mmol/L; insulin is expressed in mIU/L.
Figure 1Correlation matrix of seven attributes representing insulin resistance and insulin release. IGI30min that represents insulin release has low-level correlation with HOMA-IR (r = 0.04) and ISI (r = 0.04).
Figure 2Four groups generated according to HOMA-IR and IGI30min by the K-means clustering method. Left: The larger point at the center of each circle stands for the centroid whose means of variables are listed in Table 3. Right: The distribution of encircled patients.
Characteristics of patients in four groups regarding obesity levels, glucose metabolism, insulin resistance and β-cell function.
| Categories | Variables | Mean ± | |||||
|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | Group 4 | In Group 4 | |||
| IGT | IFG | ||||||
| Number of objects | 19 | 38 | 63 | 129 | 46 | 14 | |
| Physical examinations | Age | 24.7 ± 4.6 | 31.4 ± 9.1 | 28.4 ± 8.8 | 32.2 ± 10.3 | 36.9 ± 12.5 | 34.1 ± 7.2 |
| Weight | 114.2 ± 19.2 | 102 ± 18.5 | 91.1 ± 16.1 | 88.1 ± 15.9 | 86.7 ± 17.1 | 89.6 ± 18.4 | |
| BMI | 39.3 ± 6.1 | 35.6 ± 5.3 | 32.7 ± 4.5 | 32.3 ± 3.8 | 32.3 ± 4 | 32.5 ± 4.2 | |
| WHR | 0.95 ± 0.06 | 0.96 ± 0.06 | 0.93 ± 0.07 | 0.92 ± 0.07 | 0.94 ± 0.06 | 0.93 ± 0.07 | |
| SBP | 134 ± 12 | 138 ± 15 | 127 ± 14 | 131 ± 12 | 133 ± 13 | 128 ± 13 | |
| Laboratory measurements | HbA1C | 5.4 ± 0.4 | 5.9 ± 0.6 | 5.4 ± 0.4 | 5.5 ± 0.4 | 5.6 ± 0.4 | 5.6 ± 0.5 |
| FBG | 5.3 ± 0.6 | 6.0 ± 0.6 | 5.1 ± 0.4 | 5.4 ± 0.5 | 5.5 ± 0.7 | 6 ± 0.3 | |
| PBG30min | 8.5 ± 1.1 | 10.7 ± 1.9 | 8.1 ± 1.2 | 9.1 ± 1.3 | 9.6 ± 1.3 | 9.4 ± 1.3 | |
| PBG2h | 6.5 ± 1.7 | 8.2 ± 2.4 | 6.0 ± 1.1 | 7.3 ± 2.0 | 9.3 ± 1.5 | 6.8 ± 0.9 | |
| FINS | 61 ± 30 | 45 ± 12 | 23 ± 7 | 19 ± 6 | 20 ± 6.3 | 19.0 ± 6.1 | |
| INS30min | 423 ± 233 | 183 ± 78 | 206 ± 86 | 102 ± 48 | 95 ± 52 | 87 ± 34 | |
| INS2h | 257 ± 237 | 171 ± 97 | 105 ± 81 | 92 ± 60 | 136 ± 70 | 78 ± 50 | |
| Insulin resistance | HOMA-IR | 12.0 ± 2.3 | 11.4 ± 2.1 | 5.3 ± 1.8 | 4.6 ± 1.6 | 4.9 ± 1.6 | 5.0 ± 1.6 |
| ISI | 1.4 ± 0.6 | 1.4 ± 0.5 | 3.4 ± 1.5 | 3.6 ± 1.5 | 2.6 ± 1.0 | 3.5 ± 1.5 | |
| Insulin release (β-cell function) | HOMA-β | 555 ± 126 | 388 ± 152 | 296 ± 119 | 222 ± 106 | 221 ± 118 | 158 ± 58 |
| IGI30min | 90 ± 14.2 | 30.3 ± 14.0 | 61.4 ± 16.8 | 21.4 ± 10.4 | 18.0 ± 9.9 | 19.5 ± 5.8 | |
| 1st phase | 5354 ± 792 | 3321 ± 1207 | 3340 ± 920 | 1817 ± 657 | 1676 ± 711 | 1580 ± 465 | |
| 2nd phase | 932 ± 181 | 784 ± 185 | 564 ± 171 | 452 ± 143 | 471 ± 189 | 439 ± 131 | |
| Disposition index (DI) | 2.0 ± 1 | 0.7 ± 0.3 | 2.7 ± 1 | 1.3 ± 0.7 | 1 ± 0.6 | 1.1 ± 0.4 | |
| Interpretation | High insulin resistance, high insulin release | High insulin resistance, low insulin release | Low insulin resistance, high insulin release | Low insulin resistance, low insulin release | |||
Glucose is expressed in mmol/L; insulin is expressed in mIU/L.